© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!
Back in 2008, Velcade (bortezomib) was just being approved to treat patients with multiple myeloma. A combination called RVd — Revlimid (lenalidomide), Velcade and dexamethasone – eventually became standard of care for this patient population after it showed promising results in the SWOG S077 trial.
However, not everyone can tolerate this combination, so a new option, “RVd lite,” is being explored.
Since, 2018 has also had some major Food and Drug Administration (FDA) moves, pushing the field far beyond where it was a decade ago.
The year has been an exciting one for the treatment of myeloma, and there is sure to be even more advances made in 2019. To read more and stay up to date with all myeloma news, visit https://www.curetoday.com/tumor/myeloma
Count Me Among The Breast Cancer Recurrence Project
Counseling, Targeted Interventions Needed to Improve Health-Related Quality of Life in Young Colon Cancer Survivors
Celebrating A ‘Cancerversary’ In A COVID-19 World
Alleviating Pandemic-Related Anxiety Over Returning to the Clinic for Clinical Trials